TRX Tissue Regenix Group Plc

TIDMTRX

RNS Number : 7943T

Tissue Regenix Group PLC

18 November 2019

Tissue Regenix Group plc

Directorate Change

Leeds, 18 November 2019 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or the "Company") the regenerative medical devices company today announces that Chief Financial Officer (CFO), Mike Barker, has resigned from his position for personal reasons and will leave the Company at the end of November. Group Financial Controller, Kirsten Lund, has been appointed Group Finance Director and will resume these responsibilities with immediate effect allowing for an orderly handover. Kirsten Lund is not being appointed to the Board of the Company at the current time.

Kirsten joined Tissue Regenix in 2010 and has amassed a wealth of knowledge pertaining to the corporate structure and commercial strategy of the business.

John Samuel, Executive Chairman, Tissue Regenix Group, commented: "On behalf of the board I wish Mike well in his future endeavours. Kirsten is an excellent asset to the management team, her knowledge and understanding of the business is invaluable as we look to drive the future growth of the Company."

For more Information:

 
 Tissue Regenix Group plc                       Tel: 0330 430 3073 / 
  Caitlin Pearson Head of Communications         07920272 441 
---------------------------------------------  --------------------- 
 
 Stifel Nicolaus Europe Limited (Nominated      Tel: 0207 710 7600 
  Adviser and Broker) 
  Jonathan Senior / Alex Price / Ben Maddison 
---------------------------------------------  --------------------- 
 
 FTI Consulting                                 Tel: 0203 727 1000 
  Brett Pollard / Victoria Foster Mitchell 
  / Mary Whittow 
=============================================  ===================== 
 

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL(R) ') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

In August 2017 Tissue Regenix acquired CellRight Technologies(R) , a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

BOAGGGQCGUPBGAR

(END) Dow Jones Newswires

November 18, 2019 11:03 ET (16:03 GMT)

Tissue Regenix (LSE:TRX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Tissue Regenix (LSE:TRX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024